News & events

Press releases

Press releases

RSS Feed
31 May 2022, Sophia-Antipolis, France

Median Technologies launches Imaging Lab, spearheading the integration of iBiopsy® Artificial Intelligence technologies into iCRO imaging services for oncology trials

With Imaging Lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials by leveraging images with data mining and Artificial Intelligence (AI) technologies from iBiopsy® and radiomics. Imaging Lab’s solutions will support the pharmaceutical industry’s paradigm shift towards therapies targeting patients with early-stage cancers. The Imaging Lab team will be exhibiting at the ASCO Annual Conference in Chicago, June 3-7, 2022, Median’s booth #2098.

Read more
5 May 2022, Sophia-Antipolis, France

Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device

Median has received the FDA’s feedback following the 513(g) regulatory submission for its iBiopsy® LCS CADe/CADx Software as Medical Device. Median will proceed through a 510(k) submission to obtain an FDA device clearance and market authorization, targeted for end 2023. On May 2, 2022, Median initiated a Q-submission process, composed of several submissions, to request feedback from the FDA on various topics such as the pivotal study protocols.

Read more
21 April 2022, Sophia-Antipolis, France

Median Technologies reports full-year 2021 results and business indicators for the first quarter of 2022

Record high revenue of €5.7 million in Q1 2022, up 9.2% compared with Q1 2021 – Further growth in the order backlog to €62.3 million as of March 31, 2022, up 18.4% compared with March 31, 2021- Revenue of €20.5 million as of December 31, 2021, up 52.4% compared to December 31, 2020 – Cash and cash equivalents of €33.1 million as of March 31, 2022

Read more

Filter news articles by year

News and events

Email alerts